-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $28.57.
Several brokerages recently weighed in on NKTX. Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They issued a "buy" rating and a $25.00 target price for the company. Oppenheimer downgraded shares of Nkarta from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 22nd. Mizuho dropped their price objective on shares of Nkarta from $81.00 to $26.00 and set a "buy" rating for the company in a research note on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a "buy" rating and a $25.00 price objective for the company.
Get Nkarta alerts:Nkarta Trading Down 4.7 %
Shares of NKTX stock opened at $5.07 on Tuesday. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $11.43. Nkarta has a twelve month low of $4.83 and a twelve month high of $20.35. The company has a market capitalization of $247.49 million, a price-to-earnings ratio of -1.90 and a beta of 0.17.
Nkarta (NASDAQ:NKTX – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.04. As a group, research analysts predict that Nkarta will post -2.62 earnings per share for the current year.Institutional Trading of Nkarta
A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Parkwood LLC acquired a new stake in Nkarta during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP increased its position in Nkarta by 39.1% during the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC purchased a new position in Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new position in Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after acquiring an additional 4,147 shares during the period. Institutional investors and hedge funds own 87.22% of the company's stock.
Nkarta Company Profile
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Further Reading
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $28.57.
納卡達公司(NASDAQ:NKTX-獲取評級)已被目前覆蓋該股票的九家評級公司提供了一致的評級「中度買入」。一位股票研究分析師將該股票評級為持有評級,而八位股票則給予該公司的買入評級。去年涵蓋該股票的經紀公司的平均 1 年價格目標為 $28.57。
Several brokerages recently weighed in on NKTX. Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They issued a "buy" rating and a $25.00 target price for the company. Oppenheimer downgraded shares of Nkarta from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 22nd. Mizuho dropped their price objective on shares of Nkarta from $81.00 to $26.00 and set a "buy" rating for the company in a research note on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a "buy" rating and a $25.00 price objective for the company.
最近有幾家經紀公司在 NTX 上稱重。康雅克誠集團在 10 月 10 日星期一的研究報告中開始對 Nkarta 的股份進行報導。他們為該公司發布了「買入」評級和 25.00 美元的目標價格。奧本海默在 12 月 22 日(星期四)的一份研究報告中,將 Nkarta 的股票從「表現超越」評級降為「市場表現」評級。瑞穗將 Nkarta 股票的價格目標從 81.00 美元降至 26.00 美元,並在 11 月 16 日(週三)的一項研究報告中為該公司設定了「買入」評級。最後, 坎雅科德真正集團開始覆蓋 Nkarta 的股份在研究筆記上週一, 10 月 10 日.他們為公司設定了「買入」評級和 25.00 美元的價格目標。
Nkarta Trading Down 4.7 %
顯示交易下跌 4.7%
Shares of NKTX stock opened at $5.07 on Tuesday. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $11.43. Nkarta has a twelve month low of $4.83 and a twelve month high of $20.35. The company has a market capitalization of $247.49 million, a price-to-earnings ratio of -1.90 and a beta of 0.17.
NTX 股票的股票在周二開盤,價格為 5.07 美元。該公司的 50 天移動平均價格為 7.07 美元,200 日移動平均價為 11.43 美元。納卡達有一個十二個月低點 4.83 美元,十二個月高點為 20.35 美元。該公司的市值為 24749 萬美元,價格與收益比為 -1.90,測試版為 0.17。
Institutional Trading of Nkarta
納卡達的機構交易
A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Parkwood LLC acquired a new stake in Nkarta during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP increased its position in Nkarta by 39.1% during the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC purchased a new position in Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new position in Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after acquiring an additional 4,147 shares during the period. Institutional investors and hedge funds own 87.22% of the company's stock.
一些機構投資者和對沖基金最近買賣了 NTX 的股票。帕克伍德有限責任公司在第二季度收購了納卡達的新股份,價值約為 31,000 美元。昆特科技有限公司在第一季度增加了 39.1% 在納卡達的地位。在上一季度額外購買 900 股之後,昆博科技有限公司現在擁有該公司股票的 3,200 股價值 36,000 美元。德納利顧問有限責任公司在第二季度購買了 Nkarta 的新位置,價值約 38,000 美元。七十二點香港有限公司於第三季在 Nkarta 購入了一個價值約 46,000 美元的新倉位。最後,聯邦愛馬仕公司在第一季度將其在 Nkarta 的持有量提高了 735.3%。在此期間,聯邦愛馬仕股份有限公司現在擁有該公司股票的 4,711 股價值 54,000 美元。機構投資者和對沖基金擁有公司股票的 87.22%。
Nkarta Company Profile
納達公司簡介
(Get Rating)
(取得評分)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta, Inc 是一家臨床階段生物製藥公司,致力於開發和商業化用於癌症治療的細胞療法。該公司的細胞免疫治療方法涉及天然殺傷(NK)細胞表面的嵌合抗原受體,該細胞使細胞能夠識別出存在於腫瘤細胞表面的特定蛋白質或抗原。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
- 免費獲取有關納卡德(NTX)的研究報告
- 諾斯羅普·格魯曼拋售是一個機會嗎?
- 新的首席執行官在裝甲股票下最糟糕的背後是什麼?
- 分析師喜歡適合斯凱奇美國
- 微軟對聊天 GBT 的投資對 MSFT 股票意味著什麼?
- 我們可以相信標普 500 的反彈
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接收納卡達日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nkarta 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧